Imputation Strategies
pyrbmi implements the reference-based multiple imputation strategies defined in the ICH E9(R1) estimands framework.
Overview
| Strategy | Description | Use Case |
|---|---|---|
| MAR | Missing At Random | Standard assumption, discontinuation unrelated to outcome |
| J2R | Jump to Reference | Post-discontinuation follows reference arm trajectory |
| CR | Copy Reference | Post-discontinuation copies reference arm observations |
| CIN | Copy Increment from Reference | Post-baseline increment equals reference arm |
| LMCF | Last Mean Carried Forward | Freezes outcome at last observed value |
MAR (Missing At Random)
The standard regulatory assumption where missing data is handled under the premise that discontinuation is unrelated to the unobserved outcome.
This is the primary analysis assumption in most Phase III trials.
J2R (Jump to Reference)
After treatment discontinuation, the subject's outcome distribution "jumps" to match the reference (typically placebo) arm.
Mathematical formulation: - Pre-discontinuation: Subject follows their assigned treatment arm - Post-discontinuation: Subject's mean follows reference arm, variance from reference arm
Clinical interpretation: Assumes treatment effect is lost after discontinuation, with disease progression similar to untreated patients.
CR (Copy Reference)
The subject's post-baseline outcomes are replaced with draws from the reference arm's joint distribution.
Mathematical formulation: - Post-baseline: Outcome distribution identical to reference arm (including correlation structure)
Clinical interpretation: More extreme than J2R — assumes the subject never had any treatment effect.
CIN (Copy Increment from Reference)
The subject's post-baseline change from baseline matches the reference arm's change from baseline.
Mathematical formulation: - Post-baseline: Increment (Y_t - Y_0) follows reference arm's increment distribution
Clinical interpretation: Subject maintains their baseline value but follows reference trajectory.
LMCF (Last Mean Carried Forward)
The subject's mean outcome is frozen at their last observed value.
Mathematical formulation: - Post-discontinuation: Mean equals last observed value, variance from within-subject residual
Clinical interpretation: No disease progression after discontinuation (optimistic scenario).
Treatment Policy
Handles intercurrent events via the treatment policy estimand (ITT-like).
Choosing a Strategy
The ICH E9(R1) framework recommends:
- Primary analysis: MAR under treatment policy estimand
- Sensitivity analyses: J2R, CR, CIN to assess robustness to departures from MAR
- Tipping point: Identify thresholds where conclusions change
Implementation Notes
All strategies are implemented via the same unified API:
from pyrbmi import Strategy, Imputer
# Any strategy works with any imputation method
strategy = Strategy.jump_to_reference()
imputer = Imputer.bayesian(n_samples=200)
imputed = imputer.fit_impute(dataset, strategy=strategy)
The mathematical details (conditional distributions, covariance structures) are handled automatically based on the underlying MMRM model.